| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Maren R Laughli. Normal roles for dietary fructose in carbohydrate metabolism. Nutrients. vol 6. issue 8. 2015-04-01. PMID:25100436. |
in addition, emerging evidence suggests that fructose may also play a role in the secretion of insulin and glp-1, and in the maturation of preadipocytes to increase fat storage capacity. |
2015-04-01 |
2023-08-13 |
Not clear |
| Sindhu Rajan, Lorna M Dickson, Elizabeth Mathew, Caitlin M O Orr, Johanne H Ellenbroek, Louis H Philipson, Barton Wickstee. Chronic hyperglycemia downregulates GLP-1 receptor signaling in pancreatic β-cells via protein kinase A. Molecular metabolism. vol 4. issue 4. 2015-04-01. PMID:25830090. |
chronic hyperglycemia downregulates glp-1 receptor signaling in pancreatic β-cells via protein kinase a. glucagon-like peptide 1 (glp-1) enhances insulin secretion and protects β-cell mass. |
2015-04-01 |
2023-08-13 |
human |
| R U Ostrovskaya, N N Zolotov, I V Ozerova, E A Ivanova, I G Kapitsa, K V Taraban, A M Michunskaya, T A Voronina, T A Gudasheva, S B Seredeni. Noopept normalizes parameters of the incretin system in rats with experimental diabetes. Bulletin of experimental biology and medicine. vol 157. issue 3. 2015-03-31. PMID:25065315. |
streptozotocin was shown to decrease the concentrations of incretin glp-1 and insulin in the blood. |
2015-03-31 |
2023-08-13 |
rat |
| Marion L Vetter, Thomas A Wadden, Karen L Teff, Zahra F Khan, Raymond Carvajal, Scott Ritter, Reneé H Moore, Jesse L Chittams, Alex Iagnocco, Kenric Murayama, Gary Korus, Noel N Williams, Michael R Rickel. GLP-1 plays a limited role in improved glycemia shortly after Roux-en-Y gastric bypass: a comparison with intensive lifestyle modification. Diabetes. vol 64. issue 2. 2015-03-31. PMID:25204975. |
despite the markedly exaggerated glp-1 response after rygb, changes in postprandial glucose and insulin responses did not significantly differ between groups, and glucagon secretion was paradoxically augmented after rygb. |
2015-03-31 |
2023-08-13 |
human |
| Heather Eng, Raman Sharma, Thomas S McDonald, Margaret S Landis, Benjamin D Stevens, Amit S Kalgutka. Pharmacokinetics and metabolism studies on the glucagon-like peptide-1 (GLP-1)-derived metabolite GLP-1(9-36)amide in male Beagle dogs. Xenobiotica; the fate of foreign compounds in biological systems. vol 44. issue 9. 2015-03-30. PMID:24588343. |
glp-1(7-36)amide possesses potent insulinotropic actions in the augmentation of glucose-dependent insulin secretion. |
2015-03-30 |
2023-08-12 |
mouse |
| Vladimer Darsalia, David Nathanson, Thomas Nyström, Thomas Klein, Åke Sjöholm, Cesare Patron. GLP-1R activation for the treatment of stroke: updating and future perspectives. Reviews in endocrine & metabolic disorders. vol 15. issue 3. 2015-03-30. PMID:24777909. |
the activation of the glp-1r by glp-1 enhances glucose-dependent insulin secretion, suppresses glucagon secretion and exerts multifarious extrapancreatic effects. |
2015-03-30 |
2023-08-13 |
Not clear |
| Jeppe Sko. Effects of GLP-1 in the kidney. Reviews in endocrine & metabolic disorders. vol 15. issue 3. 2015-03-30. PMID:24791975. |
the incretin hormone, glucagon-like peptide-1 (glp-1), stimulates insulin secretion and forms the basis of a new drug class for diabetes treatment. |
2015-03-30 |
2023-08-13 |
Not clear |
| Vladimer Darsalia, Anna Olverling, Martin Larsson, Shiva Mansouri, David Nathanson, Thomas Nyström, Thomas Klein, Åke Sjöholm, Cesare Patron. Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice. Regulatory peptides. vol 190-191. 2015-03-30. PMID:24821550. |
dipeptidyl peptidase 4 (dpp-4) inhibitors are current drugs for the treatment of type 2 diabetes (t2d) based on their main property to enhance endogenous glucagon-like peptide-1 (glp-1) levels, thus increasing insulin secretion. |
2015-03-30 |
2023-08-13 |
mouse |
| Maria Saur Svane, Sten Madsba. Bariatric surgery - effects on obesity and related co-morbidities. Current diabetes reviews. vol 10. issue 3. 2015-03-30. PMID:24934290. |
some of the benefits after rygb and sg are independent of weight loss, and the remission of type 2 diabetes is observed a few days after the operation; this depends on changes in insulin sensitivity and gut hormone responses, especially a 10-fold increase in glucagon-like peptide-1 (glp-1), which improves insulin secretion. |
2015-03-30 |
2023-08-13 |
Not clear |
| Helena M de Wit, Gerald M M Vervoort, Henry J Jansen, Wim J C de Grauw, Bastiaan E de Galan, Cees J Tac. Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT). Diabetologia. vol 57. issue 9. 2015-03-30. PMID:24947583. |
we determined whether addition of a glucagon-like peptide-1 (glp-1) analogue could reverse pronounced insulin-associated weight gain while maintaining glycaemic control, and compared this with the most practised strategy, continuation and intensification of standard insulin therapy. |
2015-03-30 |
2023-08-13 |
Not clear |
| Melissa Chen, Franca S Angeli, You-Tang Shen, Richard P Shanno. GLP-1 (7-36) amide restores myocardial insulin sensitivity and prevents the progression of heart failure in senescent beagles. Cardiovascular diabetology. vol 13. 2015-03-30. PMID:25078106. |
glp-1 (7-36) amide restores myocardial insulin sensitivity and prevents the progression of heart failure in senescent beagles. |
2015-03-30 |
2023-08-13 |
Not clear |
| Melissa Chen, Franca S Angeli, You-Tang Shen, Richard P Shanno. GLP-1 (7-36) amide restores myocardial insulin sensitivity and prevents the progression of heart failure in senescent beagles. Cardiovascular diabetology. vol 13. 2015-03-30. PMID:25078106. |
we previously demonstrated that older beagles have impaired whole body and myocardial insulin responsiveness (mir), and that glucagon-like peptide-1 (glp-1 [7-36] amide) improves mir in young beagles with dilated cardiomyopathy (dcm). |
2015-03-30 |
2023-08-13 |
Not clear |
| Aiysha Thompson, Venkateswarlu Kanamarlapud. Agonist-induced internalisation of the glucagon-like peptide-1 receptor is mediated by the Gαq pathway. Biochemical pharmacology. vol 93. issue 1. 2015-03-20. PMID:25449603. |
the internalised hglp-1r stimulates insulin secretion from pancreatic β-cells, indicating the importance of glp-1 internalisation for insulin secretion. |
2015-03-20 |
2023-08-13 |
human |
| Naykky Singh Ospina, Victor M Montor. Review: in type 2 diabetes, GLP-1 agonists plus basal insulin reduce HbA1c without increasing hypoglycemia. Annals of internal medicine. vol 162. issue 2. 2015-03-19. PMID:25599366. |
review: in type 2 diabetes, glp-1 agonists plus basal insulin reduce hba1c without increasing hypoglycemia. |
2015-03-19 |
2023-08-13 |
Not clear |
| Rauza Sukma Rita, Katsuya Dezaki, Tomoyuki Kurashina, Masafumi Kakei, Toshihiko Yad. Partial blockade of Kv2.1 channel potentiates GLP-1's insulinotropic effects in islets and reduces its dose required for improving glucose tolerance in type 2 diabetic male mice. Endocrinology. vol 156. issue 1. 2015-03-13. PMID:25337656. |
kv2.1 channel blocker guangxitoxin-1e (gxtx) and glp-1 agonist exendin-4 at subthreshold concentrations, when combined, markedly increased the insulin release and cytosolic ca(2+) concentration ([ca(2+)]i) in a glucose-dependent manner in mouse islets and β-cells. |
2015-03-13 |
2023-08-13 |
mouse |
| Rauza Sukma Rita, Katsuya Dezaki, Tomoyuki Kurashina, Masafumi Kakei, Toshihiko Yad. Partial blockade of Kv2.1 channel potentiates GLP-1's insulinotropic effects in islets and reduces its dose required for improving glucose tolerance in type 2 diabetic male mice. Endocrinology. vol 156. issue 1. 2015-03-13. PMID:25337656. |
furthermore, subthreshold doses of gxtx and glp-1 agonist liraglutide in combination markedly increased plasma insulin and improved glucose tolerance in diabetic db/db mice and nsy mice. |
2015-03-13 |
2023-08-13 |
mouse |
| Nour Qa'aty, Yanting Wang, Andrew Wang, Shuai Mao, Matthew Vincent, Mansoor Husain, Aleksander Hine. The antidiabetic hormone glucagon-like peptide-1 induces formation of new elastic fibers in human cardiac fibroblasts after cross-activation of IGF-IR. Endocrinology. vol 156. issue 1. 2015-03-13. PMID:25353182. |
glucagon-like peptide 1 (glp-1) is a metabolic hormone involved in the stimulation of insulin biosynthesis and secretion. |
2015-03-13 |
2023-08-13 |
human |
| Zachary T Bloomgarde. Basal insulin or longacting GLP-1 receptor agonists-making the right choice. The lancet. Diabetes & endocrinology. vol 2. issue 6. 2015-03-12. PMID:24731676. |
basal insulin or longacting glp-1 receptor agonists-making the right choice. |
2015-03-12 |
2023-08-13 |
Not clear |
| Sergiy V Korol, Zhe Jin, Omar Babateen, Bryndis Birni. GLP-1 and exendin-4 transiently enhance GABAA receptor-mediated synaptic and tonic currents in rat hippocampal CA3 pyramidal neurons. Diabetes. vol 64. issue 1. 2015-03-11. PMID:25114295. |
glucagon-like peptide-1 (glp-1) is a hormone that stimulates insulin secretion. |
2015-03-11 |
2023-08-13 |
rat |
| G B Bolli, D R Owen. Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus. Diabetes, obesity & metabolism. vol 16. issue 7. 2015-03-09. PMID:24373190. |
recent advances in therapies for the treatment of type 2 diabetes mellitus (t2dm) have led to the development of glucagon-like peptide-1 receptor agonists (glp-1 ras), which, unlike insulin and sulphonylurea, are effective, with a low risk of hypoglycaemia. |
2015-03-09 |
2023-08-12 |
Not clear |